ArticlePancreas2017
Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions.
Article in Pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2024Pooled it
- Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review.Journal of gastrointestinal cancer · 2018Pooled it
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Clinically relevant burden of delayed gastric emptying after left pancreatectomy and its predictors.Updates in surgery · 2026Article
- Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma.Annals of surgical oncology · 2026Article
- Article
- The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.EMBO molecular medicine · 2025Article
- Impact of Preoperative Weight Loss on Prognosis in Patients with Pancreatic Cancer.Biomedicines · 2025Article
- Review
- Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.Journal of cachexia, sarcopenia and muscle · 2025Article
- Advancing the Understanding and Treatment of Cancer Cachexia: Mechanisms, Therapeutic Approaches, and Future Opportunities.Cancer management and research · 2025Review
- A scoping review of unexpected weight loss and cancer: risk, guidelines, and recommendations for follow-up in primary care.BJGP open · 2024Article
- Muscle inflammation is regulated by NF-κB from multiple cells to control distinct states of wasting in cancer cachexia.Cell reports · 2024Article
- Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia.BMC cancer · 2024Article
- Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial.Contemporary clinical trials communications · 2024Article
- Article
- Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.Internal medicine (Tokyo, Japan) · 2023Article
- Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
objectivesPancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival.
methodsConsecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models.
resultsSubstantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76-2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09-2.87).
conclusionsDespite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.